SMW Free Realtime Trade Alerts -- Our Last 2 Trade Alerts were VII and NFEC, easy 40-75% wins in minutes, Join Today for FREE!!

Geron Corporation
(NASDAQ : GERN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Loading GERN News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.79%86.551.6%$778.69m
BIIBBiogen Inc.
1.89%287.781.2%$583.61m
CELGCelgene Corporation
0.07%107.521.1%$489.51m
AMGNAmgen Inc.
0.90%165.671.2%$488.57m
REGNRegeneron Pharmaceuticals, Inc.
0.47%391.343.1%$323.98m
ALXNAlexion Pharmaceuticals, Inc.
-1.18%125.802.6%$289.82m
TSROTESARO, Inc.
-0.05%91.9918.0%$215.68m
BMRNBioMarin Pharmaceutical Inc.
0.24%93.583.9%$197.30m
ILMNIllumina, Inc.
-0.36%150.765.1%$188.17m
MDVNMedivation, Inc.
0.14%62.632.6%$145.51m
VRTXVertex Pharmaceuticals Incorporated
0.73%93.891.7%$132.65m
JUNOJuno Therapeutics, Inc.
1.04%29.137.9%$106.11m
AAgilent Technologies, Inc.
-0.21%46.571.9%$100.85m
INCYIncyte Corporation
-1.57%86.412.2%$87.30m
ACADACADIA Pharmaceuticals Inc.
1.36%36.5513.1%$79.16m

Company Profile

Geron Corp. discovers and develops therapeutic products for cancer. It is a clinical stage biopharmaceutical company developing a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company's imetelstat, their sole product candidate, is a potent and specific inhibitor of telomerase. Based on clinical data, they may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or MF, which includes patients with primary MF, post-essential thrombocythemia MF, myelodysplastic syndromes, acute myelogenous leukemia. Geron was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.